Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SHH | Q15465 | 1/20 | 0.34 |
| ▸ | SMO | Q99835 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.32 |
| ▸ | UBE2M | P61081 | 3/20 | 0.32 |
| ▸ | DCUN1D1 | Q96GG9 | 3/20 | 0.32 |
| ▸ | BMP1 | P13497 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2795842 | 0.92 | SHH (0.35) | SHHSMOKCNH2LMNAOPRM1 | |
| SCHEMBL2798079 | 0.92 | SHH (0.36) | SHHSMOKCNH2LMNAOPRM1 | |
| SCHEMBL2800697 | 0.89 | SHH (0.35) | SHHSMOKCNH2LMNAOPRM1 | |
| SCHEMBL5042242 | 0.89 | KCNH2 (0.41) | KCNH2LMNAOPRM1UBE2MDCUN1D1 | |
| SCHEMBL5042240 | 0.89 | KCNH2 (0.41) | KCNH2LMNAOPRM1UBE2MDCUN1D1 | |
| SCHEMBL2799131 | 0.87 | KCNH2 (0.36) | SHHSMOKCNH2LMNAOPRM1 | |
| SCHEMBL2800210 | 0.86 | SHH (0.36) | SHHSMOKCNH2LMNAOPRM1 | |
| SCHEMBL2800492 | 0.85 | KCNH2 (0.46) | SHHSMOKCNH2LMNAOPRM1 | |
| SCHEMBL2801132 | 0.85 | KCNH2 (0.38) | SHHSMOKCNH2LMNAOPRM1 | |
| SCHEMBL2796269 | 0.84 | KCNH2 (0.47) | SHHSMOKCNH2LMNAUBE2M |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8329694-B2 | Quinoxalinones as antibacterial composition | TOYAMA CHEMICAL CO., LTD. (JP) | 2012-12-11 | — | — | US | disclosed |
| US-20100168418-A1 | NOVEL NITROGENATED HETEROCYCLIC COMPOUND AND SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2010-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168418-A1 | NOVEL NITROGENATED HETEROCYCLIC COMPOUND AND SALT THEREOF | ROS1, NOX1, ARG1 | SHH 1455/4885SMO 1036/4885KCNH2 578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.